

PERSONAL INFORMATION

Ingrid Garajová

📍 Medical Oncology Unit, University Hospital of Parma, 43126 Parma (Italy)

📞 0039521702753

✉ ingegarajova@gmail.com

📅 Date of birth: 2.11.1980 a Nova Bana (Slovakia)

STUDIES APPLIED FOR

ONCOLOGIST, PHD IN ONCOLOGY

WORK EXPERIENCE

-
- 1/6/18–Present **Oncologist**
Medical Oncology Unit, University Hospital of Parma, Parma (Italy)
Focused on gastrointestinal cancers.
- 30/6/15–31/5/18 **Oncologist**
Sant'Orsola-Malpighi Hospital, Bologna, Bologna (Italy)
Focused on gastrointestinal cancers.
- 1/5/14–15/4/15 **Internship in Cancer Center Amsterdam**
Oncology Department, VU University Medical Center, Cancer Center Amsterdam, Amsterdam (Netherlands)
My projects concerned microRNA as diagnostic, prognostic and predictive biomarkers in solid tumors. Tutor: Dr. Elisa Giovannetti and prof. Henk Verheul.
- 18/5/10–18/5/15 **Specialization training in Oncology**
Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale (DIMES), University of Bologna, Sant'Orsola-Malpighi Hospital, Bologna (Italy)
- 1/1/10–30/4/10 **Medical doctor**
Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale (DIMES), University of Bologna, Sant'Orsola-Malpighi Hospital, Bologna (Italy)
- 1/11/08–30/6/09 **EMBO Research Fellowship**
Department of Cell Biology and Oncology (DCBO), Laboratory of G-protein-mediated signaling, Consorzio Mario Negri Sud, Santa Maria Imbaro (Italy)
Project: "The role and the regulation of the endogenous β subunit mono-ADP ribosylation in the signal transduction pathways that are mediated by the heterotrimeric G proteins". Tutor: Dr. Mariella Di Girolamo.
- 3/10/05–30/11/09 **Medical doctor in Oncology Department**
Masaryk Memorial Cancer Institute, Brno (Czech Republic)

EDUCATION AND TRAINING

-
- 18/5/10–18/5/15 **Specialization in Oncology**

Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale (DIMES), University of Bologna, Sant'Orsola-Malpighi Hospital, Bologna (Italy)

Thesis of my specialization: The role of microRNA as diagnostic, prognostic and predictive biomarkers in solid tumors. Tutor: prof. Guido Biasco.

3/10/05–23/6/09 **PhD in Oncology**
University of Masaryk, Brno (Czech Republic)

PhD thesis: "Possibilities of resistance prediction to neoadjuvant concomitant chemoradiotherapy in the treatment algorithm of patients with rectal carcinoma". Tutor: prof. Rostislav Vyzula.

1/9/98–30/5/05 **Medical degree**
Comenius University, Bratislava, Bratislava (Slovakia)

Thesis: "Molecular diagnosis of the hereditary form of breast tumors." Department of Experimental Oncology, Slovak Academia of Sciences. Speaker: Dr. Vladimír Zajac. Rector's Award for the thesis.

During the period of the University I was a guest as an ERASMUS student at the Faculty of Medicine of the University of Parma, Italy (October 2002 - February 2003). I have also participated in various foreign training courses, especially in Spain (Marques de Valdecilla Hospital, University of Cantabria, Department of Oncology, Dr. Jaime Sanz Ortiz), Italy (Brescia Hospital, training in the Department of Biomedical Sciences and Biotechnology, Prof. Rita Rezzani), Egypt (Greater Hospital of Alexandria Hospital, Internal Medicine Training, Dr. Ahmed Helali).

PERSONAL SKILLS

Mother tongue(s) Slovak

Foreign language(s)

	UNDERSTANDING		SPEAKING		WRITING
	Listening	Reading	Spoken interaction	Spoken production	
Czech	C2	C2	C2	C2	C2
English	C1	C1	C1	C1	C1
Italian	C2	C2	C2	C2	C2

Levels: A1 and A2: Basic user - B1 and B2: Independent user - C1 and C2: Proficient user
Common European Framework of Reference for Languages

Other skills Member of AIOM and ESMO.

ADDITIONAL INFORMATION

Publications **BOOK CHAPTERS**

3) Van Der Steen N, **Garajova I**, Rolfo C, Cavazzoni A, Giovannetti E. Targeting the hepatocyte growth factor receptor to overcome resistance to target therapies (chapter 2) in book "Targeting Cell Survival Pathways to Enhance Response to Chemotherapy", 2017. In print.

2) **Garajová I**, Le Large TY, Giovannetti E, Kazemier G, Biasco G, Peters GJ.: *The Role of MicroRNAs in Resistance to Current Pancreatic Cancer Treatment: Translational Studies and Basic Protocols for Extraction and PCR Analysis*. Cancer Drug Resistance, Edited by José Rueff, António Sebastião Rodrigues, 03/2016: Chapter Overviews and Methods: pages 163-87; Springer New York., ISBN: 978-1-4939-3347-1

1) Brandi et al.: *Follow-up in Oncologia: Dalla Pratica clinica all'evidenza costi/efficacia*. Chapters: **Ingrid Garajová**: Follow-up nel cancro del retto. Follow-up nel cancro dell'ano.: pages 363; Bononia University Press 2015., ISBN: 978-88-6923-007-3.

JOURNALS

- 27) Ingrid **Garajová**, Rita Balsano, Chiara Tommasi, Elisa Giovannetti: *Noncoding RNAs emerging as novel biomarkers in pancreatic cancer*. Current Pharmaceutical Design 01/2019; 25., DOI:10.2174/1381612825666190119125804
- 26) S. Tavorari, M. Deserti, F. Vasuri, S. Curti, A. Palloni, A.D. Pinna, M. Cescon, G. Frega, S. De Lorenzo, M.A. Barbera, I. Garajova, L. Ricciardiello, D. Malvi, A. D'Errico-Grigioni, M.A. Pantaleo, G. Brandi: *Membrane human equilibrative nucleoside transporter 1 is associated with a high proliferation rate and worse survival in resected intrahepatic cholangiocarcinoma patients not receiving adjuvant treatments*. DOI:10.1016/j.ejca.2018.11.005
- 25) Laura L. Meijer, Ingrid **Garajová**, Chiara Caparello, Tessa Y. S. Le Large, Adam E. Frampton, Enrico Vasile, Niccola Funel, Geert Kazemier, Elisa Giovannetti: *Plasma miR-181a-5p Downregulation Predicts Response and Improved Survival After FOLFIRINOX in Pancreatic Ductal Adenocarcinoma*. Annals of Surgery 11/2018;., DOI:10.1097/SLA.0000000000003084
- 24) Matteo Ravaioli, Guido Fallani, Matteo Cescon, Enrico Prosperi, Vanessa De Pace, Antonio Siniscalchi, Gabriela Sangiorgi, Manuela Ferracin, Andrea Ardizzoni, Maria Cristina Morelli, **Ingrid Garajová**: *Heterotopic auxiliary segment 2–3 liver transplantation with delayed total hepatectomy: New strategies for nonresectable colorectal liver metastases*. Surgery 07/2018; 164(3)., DOI:10.1016/j.surg.2018.05.021.
- 23) Giovanni Brandi, Michela Venturi, Stefania De Lorenzo, Francesca Garuti, Giorgio Frega, Andrea Palloni, Ingrid Garajová, Francesca Abbati, Gioconda Saccoccio, Rita Golfieri, Maria Abbondanza Pantaleo, Maria Aurelia Barbera: *Sustained complete response of advanced hepatocellular carcinoma with metronomic capecitabine: A report of three cases*. 06/2018; 38(1):41., DOI:10.1186/s40880-018-0312-1.
- 22) Stefania De Lorenzo, Francesco Tovoli, Maria Aurelia Barbera, Francesca Garuti, Andrea Palloni, Giorgio Frega, Ingrid Garajová, Alessandro Rizzo, Franco Trevisani, Giovanni Brandi: *Metronomic capecitabine vs. best supportive care in Child-Pugh B hepatocellular carcinoma: A proof of concept*. Scientific Reports 12/2018; 8(1)., DOI:10.1038/s41598-018-28337-6.
- 21) Porcellini E, Laprovitera N, Riefolo M, Ravaioli M, **Garajova I**, Ferracin M. Epigenetic and epitranscriptomic changes in colorectal cancer: Diagnostic, prognostic, and treatment implications. Cancer Lett. 2018;419:84-95. doi: 10.1016/j.canlet.2018.01.049.
- 20) **Ingrid Garajová**, Manuela Ferracin, Elisa Porcellini, Andrea Palloni, Francesca Abbati, Guido Biasco, Giovanni Brandi: *Non-Coding RNAs as Predictive Biomarkers to Current Treatment in Metastatic Colorectal Cancer*. International Journal of Molecular Sciences 07/2017; 18(7):1547., DOI:10.3390/ijms1807154.
- 19) Giorgio Frega, **Ingrid Garajová**, Andrea Palloni, Maria Aurelia Barbera, Marco Trossello Pastore, Luca Faccioli, Luca Spinardi, Stefania De Lorenzo, Marta Cubelli, Maria Abbondanza Pantaleo, Guido Biasco, Giovanni Brandi. *Brain metastases from biliary tract cancer: a monocentric retrospective analysis of 450 patients*. Oncology 2017, DOI: 10.1159/000479929
- 18) Palloni A, Mollica V, Ferraci M, Frega G, Maggio I, Giovannetti E, Caparello C, Biasco G, **Garajová I**. Role of microRNA in IPMN lesions. JOP, accepted March 06th, 2017.
- 17) Francesco Tovoli, Stefania De Lorenzo, Maria Aurelia Barbera, **Ingrid Garajova**, Giorgio Frega, Andrea Palloni, Maria Abbondanza Pantaleo, Guido Biasco, Giovanni Brandi: *Postsorafenib systemic treatments for hepatocellular carcinoma: questions and opportunities after the regorafenib trial*. Future Oncology 07/2017;., DOI:10.2217/fon-2017-0166
- 16) Chiara Caparello, Enrico Vasile, **Ingrid Garajova**, Asif Ali, Elisa Giovannetti: *Oxaliplatin in pre-*

treated patients: Maybe not the match point?. *Translational Cancer Research* 02/2017; 6(1):S163-S167., DOI:10.21037/tcr.2017.01.35

15) Li G, Cavazzoni A, Giovannetti E, Barbera MA, Frega G, Biasco G, **Garajová I**. *MicroRNA as predictive biomarkers for drug resistance and sensitivity in colorectal cancer*. *BELG J MED ONCOL* 2017;11(1):22-29.

14) Brandi G, Deserti M, Vasuri F, Farioli A, Degiovanni A, Palloni A, Frega G, Barbera MA, de Lorenzo S, **Garajova I**, Di Marco M, Pinna AD, Cescon M, Cucchetti A, Ercolani G, D'Errico-Grigioni A, Pantaleo MA, Biasco G, Tavolari S. In Reply. *Oncologist*. 2016 Dec;21(12):e5-e6.

13) Giovanni Brandi, Marzia Deserti, Francesco Vasuri, Andrea Farioli, Alessio Degiovanni, Andrea Palloni, Giorgio Frega, Maria A Barbera, Stefania de Lorenzo, **Ingrid Garajova**, Mariacristina Di Marco, Antonio D Pinna, Matteo Cescon, Alessandro Cucchetti, Giorgio Ercolani, A. D'Errico-Grigioni, Maria A Pantaleo, Guido Biasco, Simona Tavolari: *Membrane Localization of Human Equilibrative Nucleoside Transporter 1 in Tumor Cells May Predict Response to Adjuvant Gemcitabine in Resected Cholangiocarcinoma Patients*. *The Oncologist* 03/2016; 21(5). DOI:10.1634/theoncologist.2015-0356

12) Chiara Caparello, Laura L Meijer, **Ingrid Garajova**, Alfredo Falcone, Tessa Y Le Large, Niccola Funel, Geert Kazemier, Godefridus J Peters, Enrico Vasile, Elisa Giovannetti: *FOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancer*. *World Journal of Gastroenterology* 01/2016; 22(31). DOI:10.3748/wjg.v22.i31.6987

11) Giorgio Frega, **Ingrid Garajová**, Andrea Palloni, Stefania De Lorenzo, Maria Aurelia Barbera and Giovanni Brandi: *Clinical Features of the Intrahepatic and Extrahepatic Cholangiocarcinoma*. *World Journal of Oncology Research*, 2016, 3, 21-26 21.

10) **Ingrid Garajová**, Niccola Funel, Michelangelo Fiorentino, Valentina Agostini, Manuela Ferracin, Massimo Negrini, Giovanni Luca Frassinetti, Giampaolo Gavelli, Adam Enver Frampton, Guido Biasco, Elisa Giovannetti: *MicroRNA profiling of primary pulmonary enteric adenocarcinoma in members from the same family reveals some similarities to pancreatic adenocarcinoma-a step towards personalized therapy*. *Clinical Epigenetics* 12/2015; 7(1):129. DOI:10.1186/s13148-015-0162-5

9) **Ingrid Garajova**, Elisa Giovannetti, Guido Biasco and Godefridus J. Peters: *c-Met as a Target for Personalized Therapy*. *Translational Oncogenomics* 11/2015; 7(Suppl 1):13. DOI:10.4137/TOG.S30534

8) **Ingrid Garajová**, Elisa Giovannetti, Sara Caponi, Annette van Zweeden, Godefridus J. Peters: *MiRNAs and Their Interference with the Main Molecular Mechanisms Responsible for Drug Resistance in Pancreatic Cancer*. 08/2015; 1(4). DOI:10.1007/s40495-014-0008-4

7) **Ingrid Garajová**, Tessa Y Le Large, Adam E Frampton, Christian Rolfo, Johannes Voortman, Elisa Giovannetti: *Molecular Mechanisms Underlying the Role of MicroRNAs in the Chemoresistance of Pancreatic Cancer*. *BioMed Research International* 08/2014; 2014:678401. DOI:10.1155/2014/678401

6) **I Garajová**, G Nepoti, M Paragona, G Brandi, G Biasco: *Port-a-Cath-related complications in 252 patients with solid tissue tumours and the first report of heparin-induced delayed hypersensitivity after Port-a-Cath heparinisation*. *European Journal of Cancer Care* 09/2012; 22(1). DOI:10.1111/ecc.12008

5) Giovanni Brandi, Jody Corbelli, Francesco de Rosa, Stefania Di Girolamo, Ciro Longobardi, Valentina Agostini, **Ingrid Garajová**, Stefano La Rovere, Giorgio Ercolani, Gian Luca Grazi, Antonio Daniele Pinna, Guido Biasco: *Second surgery or chemotherapy for relapse after radical resection of colorectal cancer metastases*. *Langenbeck s Archives of Surgery* 06/2012; 397(7). DOI:10.1007/s00423-012-0974-0

4) **Ingrid Garajová**, Stefania Di Girolamo, Francesco de Rosa, Jody Corbelli, Valentina Agostini, Guido Biasco, Giovanni Brandi: *Neoadjuvant Treatment in Rectal Cancer. Actual Status*. 09/2011; 2011(8):839742. DOI:10.1155/2011/839742

3) O Slaby, K Sobkova, M Svoboda, **I Garajova**, P Fabian, R Hrstka, R Nenutil, M Sachlova, I Kocakova, J Michalek, T Smerdova, D Knoflickova, R Vyzula: *Significant overexpression of Hsp110 gene during colorectal cancer progression*. *Oncology Reports* 06/2009; 21(5):1235-41. DOI:10.3892/or_00000346

2) **I Garajová**, M Svoboda, O Slabý, I Kocáková, P Fabian, I Kocák, R Vyzula: *Possibilities of resistance prediction to neoadjuvant concomitant chemoradiotherapy in the treatment algorithm of patients with rectal carcinoma*. *Klinická onkologie: časopis České a Slovenské onkologické společnosti* 02/2008; 21(6):330-7.

1) **I Garajová**, O Slabý, M Svoboda, P Fabian, J Silák, T Smerdová, I Kocák, J Růžicková, J Hoch, R Vyzula: *Gene expression profiling in prediction of tumor response to neoadjuvant concomitant chemoradiotherapy in patients with locally advanced rectal carcinoma: Pilot Study*. *Cas Lek Ces* 02/2008; 147(7):381-6.

Granta and certifications

- 05/10/2017: AISP congress: among the winners for best presentations ("Locally advanced pancreatic ductal adenocarcinoma: circulating microRNAs in extracellular vesicles as new dynamic biomarkers of response to FOLFIRINOX chemotherapy")
- ALMA IDEA GRANT JUNIOR 2017: project collaborator "Identification of prognostic biomarkers for stage II colon cancer" (PI Manuela Ferracin)
- Basic Life Support Defibrillation, Bologna 2015

Declaration

I declare to possess the above-mentioned formative and professional experiences

Parma, 01/02/2019
Ingrid Garajová

